It revealed that DLGAP5 expression level increased in BC, breast cancer, cervical squamous carcinoma, cholangiocarcinoma, colon adenocarcinoma, esophageal carcinoma, glioblastoma multiforme, head, and neck squamous cell carcinoma, kidney cancer, hepatocellular liver carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic adenocarcinoma, rectum adenocarcinoma, prostate adenocarcinoma, stomach adenocarcinoma, thyroid carcinoma, and uterine corpus endometrial carcinoma (Figure 1A). This evidence concerns the gene DLGAP5 and thyroid gland carcinoma.